Resilience-TARGET: RNA nanotechnology delivery platform for RNA therapies
Resilience-TARGET:用于 RNA 治疗的 RNA 纳米技术递送平台
基本信息
- 批准号:10024735
- 负责人:
- 金额:$ 12.33万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Collaborative R&D
- 财政年份:2021
- 资助国家:英国
- 起止时间:2021 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
TARGET aims to preclinically validate Sixfold's Programmable Oligonucleotide Delivery System, Mergo, for delivery of short-interfering RNA (siRNA) gene silencing cargo to specific cells. By taking advantage of the interdisciplinary and complementary expertise of the partners --Sixfold and Medicine Discovery Catapult (MDC)-- the project allows for rapid scientific and commercial progress directed at early R&D collaboration and licensing with identified pharmaceutical companies.Compared to small molecule and antibody-based drugs, siRNAs can act on virtually unrestricted choice of --otherwise "undruggable"-- therapeutic targets, with high specificity and potency; while their easy manufacturing allows for rapid lead optimization \[1\]. As such, siRNAs have the potential to provide effective treatment options for diverse diseases including cancer. The first regulatory approvals of Alnylam's siRNA therapies for liver disorders in 2018-19 \[1-2\] have validated the clinical and commercial opportunity for such therapies. However, the major limiting factor for their further success remains the lack of effective systems for systemic delivery of siRNAs to specific diseased cells \[4\]. Current approaches, primarily GalNAc-conjugates, lipid nanoparticles and viral vectors, are sub-optimal given their limited cell targeting specificity, cargo loading capacity, high toxicity, and complex/expensive manufacturing that limit the type of addressable disease indications.The Mergo platform can address this drug delivery challenge given its modular design based on a central RNA nanoscaffold, which can be functionalised with therapeutics and targeting molecules that recognise biomarkers on cancer -but not healthy- cells. Although first-generation Mergo demonstrated promising _in vitro_ and _in vivo_ results, with highly competitive safety and favourable cost profiles, the efficacy remains to be optimised.TARGET validates a novel cargo attachment system to increase Mergo' cargo loading capacity, allowing for improvements in efficacy. This will also enhance Mergo versatility and speed of development, i.e. ability to readily adapt to delivery of multiple, different cargo types, creating an intelligent delivery system that goes beyond the limitations of current standards. As such, Mergo represent an attractive opportunity to capture a significant portion of the thriving gene therapy delivery market and could accelerate other Advanced Therapy Medicinal Products, through improved safety, efficacy and reduced cost of goods, especially compared to viral technologies.MDC's unique expertise in advanced preclinical imaging allows for completion of preclinical datapack to pharmaceutical industry standards and requirements for rapid commercialization and clinical advancement via licensing.Sixfold's broad IP portfolio and licensing strategy engage the entire biopharmaceutical supply chain, providing diverse benefits to the wider UK life sciences sector.\[1\]Lam\_J.K.W\_et\_al.\__Mol\_Ther\_Nucleic\_Acids_\_2015\_4(9):e252.\[2\]Alnylam\_Press\_release\_10\_August\_2018.\[3\]Alnylam\_Press\_release\_20\_November\_2019.\[4\]Payne\_D\__Nature_\_574\_S1\_2019\.
TARGET旨在临床前验证Sixfold的可编程寡核苷酸递送系统Mergo,用于向特定细胞递送短干扰RNA(siRNA)基因沉默货物。通过利用合作伙伴-Sixfold和Medicine Discovery Catapult(MDC)-的跨学科和互补专业知识,该项目可以快速实现科学和商业进展,旨在与指定的制药公司进行早期研发合作和许可。与小分子和基于抗体的药物相比,siRNA可以作用于几乎不受限制的选择-否则“无法用药”-治疗靶点,具有高特异性和效力;而它们的易于制造允许快速的铅优化[1]。因此,siRNA具有为包括癌症在内的多种疾病提供有效治疗选择的潜力。Alnylam的siRNA疗法在2018-19年首次获得监管批准\[1-2\],验证了此类疗法的临床和商业机会。然而,其进一步成功的主要限制因素仍然是缺乏将siRNA系统性递送至特定病变细胞的有效系统[4]。目前的方法,主要是GalNAc-缀合物、脂质纳米颗粒和病毒载体,由于其有限的细胞靶向特异性、货物装载能力、高毒性和复杂/昂贵的制造,限制了可寻址疾病适应症的类型,因此是次优的Mergo平台可以解决这种药物递送挑战,因为其模块化设计基于中央RNA纳米支架,它可以被治疗剂和靶向分子功能化,这些分子识别癌症细胞上的生物标志物,但不识别健康细胞。尽管第一代Mergo在体外和体内试验中取得了良好的效果,具有极具竞争力的安全性和有利的成本,但其功效仍有待优化。TARGET验证了一种新型货物附着系统,以增加Mergo的货物装载能力,从而提高功效。这也将提高Mergo的多功能性和开发速度,即能够随时适应多种不同货物类型的交付,创造一个超越当前标准限制的智能交付系统。因此,Mergo代表了一个有吸引力的机会,可以抓住蓬勃发展的基因治疗市场的重要部分,并可以通过提高安全性,有效性和降低商品成本来加速其他先进治疗药物产品,MDC在先进的临床前成像方面的独特专业知识允许完成符合制药行业标准和快速商业化要求的临床前数据包Sixfold广泛的知识产权组合和许可策略涉及整个生物制药供应链,为更广泛的英国生命科学行业提供多样化的利益。[1] Lam J.K.W等人《分子核酸》2015年第4期第9卷:e252页。[2\]Alnylam\_Press\_release\_10\_August\_2018.\ [3\]Alnylam\_Press\_release\_20\_November\_2019.\ [4\]Payne\_D\__Nature_\_574\_S1\_2019\.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
其他文献
吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('', 18)}}的其他基金
An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
- 批准号:
2901954 - 财政年份:2028
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
- 批准号:
2896097 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
- 批准号:
2780268 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
- 批准号:
2908918 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
- 批准号:
2908693 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
- 批准号:
2908917 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
- 批准号:
2879438 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
- 批准号:
2890513 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
- 批准号:
2879865 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
- 批准号:
2876993 - 财政年份:2027
- 资助金额:
$ 12.33万 - 项目类别:
Studentship
相似国自然基金
应用Target-Seq技术对肉牛生长性状显著关联基因组区域进行精细定位
- 批准号:31402039
- 批准年份:2014
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Search for therapeutic target molecules based on temporal hierarchical analysis of Oral squamous cell carcinoma and functional RNA molecules
基于口腔鳞状细胞癌和功能RNA分子的时间层次分析寻找治疗靶分子
- 批准号:
23K16142 - 财政年份:2023
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ultrasensitive, Rapid, Amplification-Free RNA Virus Detection Using Nanodimer-Based Nucleic Acid Target Sequence Recognition
使用基于纳米二聚体的核酸靶序列识别进行超灵敏、快速、无扩增的 RNA 病毒检测
- 批准号:
2232940 - 财政年份:2023
- 资助金额:
$ 12.33万 - 项目类别:
Standard Grant
Construction of Artificial Nucleic Acids with Highly Active Catalytic Target RNA Cleavage Ability and Development as a Therapeutic Platform
具有高活性催化靶RNA切割能力的人工核酸的构建及其作为治疗平台的开发
- 批准号:
23H05465 - 财政年份:2023
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Scientific Research (S)
3D multi-target imaging of RNA virus replication deep in cells at the nanoscale
纳米级细胞深处 RNA 病毒复制的 3D 多目标成像
- 批准号:
576850-2022 - 财政年份:2022
- 资助金额:
$ 12.33万 - 项目类别:
Alliance Grants
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
RNA 聚合酶 II 作为急性髓系白血病 (AML) 的治疗靶点并激活 RAS 信号转导
- 批准号:
10657800 - 财政年份:2022
- 资助金额:
$ 12.33万 - 项目类别:
The role of the RNA helicase DDX3X in Burkitt Lymphoma and its potential as a new therapeutic target
RNA解旋酶DDX3X在伯基特淋巴瘤中的作用及其作为新治疗靶点的潜力
- 批准号:
461753 - 财政年份:2022
- 资助金额:
$ 12.33万 - 项目类别:
Operating Grants
Immune cell skewing with RNA target site oligonucleotides to promote vascular smooth muscle cell homeostasis
RNA靶位点寡核苷酸倾斜免疫细胞促进血管平滑肌细胞稳态
- 批准号:
10593490 - 财政年份:2022
- 资助金额:
$ 12.33万 - 项目类别:
microRNA target site RNA-directed oligonucleotide topical therapeutics in psoriasis
microRNA 靶位点 RNA 引导的寡核苷酸局部治疗银屑病
- 批准号:
10287633 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
Development of turn-on fluorescent RNA aptamer to visualize target proteins in vivo
开发开启荧光RNA适体以在体内可视化靶蛋白
- 批准号:
21K19041 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
microRNA target site RNA-directed oligonucleotide topical therapeutics in psoriasis
microRNA 靶位点 RNA 引导的寡核苷酸局部治疗银屑病
- 批准号:
10426347 - 财政年份:2021
- 资助金额:
$ 12.33万 - 项目类别: